ORs (95% CIs) of mortality post ischaemic stroke based on prior therapy
| Mortality | Unadjusted | Model A | Model B | Model C |
| 0–7 days, N | 2838 | 2838 | 2654 | 2530 |
| No therapy* | 1.00 | 1.00 | 1.00 | 1.00 |
| Aspirin | 1.07 (0.78 to 1.46) | 0.99 (0.73 to 1.36) | 1.05 (0.74 to 1.48) | 0.92 (0.64 to 1.34) |
| Aspirin plus dipyridamole | 1.03 (0.44 to 2.41) | 0.95 (0.40 to 2.23) | 1.18 (0.50 to 2.83) | 0.94 (0.38 to 2.37) |
| Clopidogrel | 0.93 (0.33 to 2.61) | 0.96 (0.34 to 2.71) | 1.26 (0.44 to 3.59) | 1.79 (0.59 to 5.45) |
| Warfarin | 1.32 (0.77 to 2.30) | 1.29 (0.74 to 2.25) | 1.28 (0.69 to 2.38) | 1.40 (0.72 to 2.72) |
| 0–30 days, N | 2838 | 2838 | 2654 | 2530 |
| No therapy* | 1.00 | 1.00 | 1.00 | 1.00 |
| Aspirin | 1.18 (0.96 to 1.46) | 1.05 (0.85 to 1.30) | 1.01 (0.80 to 1.28) | 0.90 (0.70 to 1.17) |
| Aspirin plus dipyridamole | 0.84 (0.45 to 1.57) | 0.73 (0.39 to 1.38) | 0.75 (0.38 to 1.47) | 0.60 (0.29 to 1.26) |
| Clopidogrel | 0.98 (0.49 to 1.94) | 1.05 (0.52 to 2.13) | 1.17 (0.56 to 2.48) | 1.67 (0.75 to 3.71) |
| Warfarin | 1.15 (0.77 to 1.72) | 1.09 (0.73 to 1.65) | 1.02 (0.65 to 1.60) | 0.88 (0.52 to 1.49) |
| 0–60 days, N | 2838 | 2838 | 2654 | 2525 |
| No therapy* | 1.00 | 1.00 | 1.00 | 1.00 |
| Aspirin | 1.18 (0.98 to 1.43) | 1.03 (0.85 to 1.26) | 1.00 (0.81 to 1.23) | 0.90 (0.71 to 1.14) |
| Aspirin plus dipyridamole | 0.77 (0.44 to 1.37) | 0.66 (0.37 to 1.18) | 0.69 (0.38 to 1.28) | 0.55 (0.28 to 1.09) |
| Clopidogrel | 1.04 (0.57 to 1.92) | 1.15 (0.61 to 2.16) | 1.07 (0.53 to 2.15) | 1.49 (0.70 to 3.16) |
| Warfarin | 1.32 (0.93 to 1.88) | 1.25 (0.87 to 1.79) | 1.23 (0.83 to 1.82) | 1.20 (0.76 to 1.89) |
| 0–90 days, N | 2838 | 2838 | 2654 | 2525 |
| No therapy* | 1.00 | 1.00 | 1.00 | 1.00 |
| Aspirin | 1.18 (0.98 to 1.42) | 1.02 (0.85 to 1.24) | 0.99 (0.80 to 1.21) | 0.90 (0.72 to 1.14) |
| Aspirin plus dipyridamole | 0.79 (0.46 to 1.36) | 0.66 (0.38 to 1.16) | 0.71 (0.40 to 1.28) | 0.58 (0.30 to 1.12) |
| Clopidogrel | 1.09 (0.61 to 1.94) | 1.21 (0.66 to 2.21) | 1.17 (0.60 to 2.26) | 1.64 (0.80 to 3.34) |
| Warfarin | 1.40 (1.00 to 1.96) | 1.31 (0.93 to 1.86) | 1.26 (0.86 to 1.85) | 1.28 (0.82 to 1.98) |
| 0–365 days, N | 2838 | 2838 | 2654 | 2525 |
| No therapy* | 1.00 | 1.00 | 1.00 | 1.00 |
| Aspirin | 1.18 (1.00 to 1.40) | 1.00 (0.84 to 1.19) | 0.96 (0.80 to 1.16) | 0.90 (0.73 to 1.10) |
| Aspirin plus dipyridamole | 0.96 (0.60 to 1.52) | 0.78 (0.48 to 1.27) | 0.81 (0.49 to 1.35) | 0.66 (0.37 to 1.17) |
| Clopidogrel | 1.06 (0.63 to 1.80) | 1.20 (0.68 to 2.10) | 1.10 (0.60 to 2.02) | 1.45 (0.75 to 2.78) |
| Warfarin | 1.22 (0.89 to 1.68) | 1.10 (0.79 to 1.54) | 1.10 (0.77 to 1.58) | 1.06 (0.71 to 1.59) |
Model A: adjusted for age, age squared, and gender.
Model B: adjusted for age, age squared, gender and premorbid Rankin score.
Model C: adjusted for age, age squared, gender, premorbid Rankin score and Oxfordshire Community Stroke Project (OCSP) stroke type.
↵* Reference category.